Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not hel
Apellis Pharmaceuticals, Inc. (APLS) shares rallied 135.4% in the last trading session to close at $40.23. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.4% loss over the past four weeks.
Apellis stock surged 135.4% on Tuesday after Biogen $BIIB announced a $5.6 billion all-cash acquisition of the company at $41 per share, representing approximately 86% premium to its 90-day average price, along with additional contingent payments tied to Syfovre sales milestones. The deal highlights the strong commercial value of Apellis’ two approved drugs, Empaveli and Syfovre, which generated $689 million in 2025 revenue with mid-to-high teens growth expected through 2028. It also signals meaningful EPS accretion and long-term growth potential for Biogen, making the offer highly attractive to investors.
This company is expected to post quarterly loss of $0.38 per share in its upcoming report, which represents a year-over-year change of +48.7%. Revenues are expected to be $200.75 million, up 20.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Apellis Pharmaceuticals, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on APLS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Apellis Pharmaceuticals is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Autolus Therapeutics PLC Sponsored ADR (AUTL), finished the last trading session 8.7% higher at $1.38. AUTL has returned -24% over the past month.
For Autolus Therapeutics, the consensus EPS estimate for the upcoming report has changed -17.9% over the past month to -$0.31. This represents a change of -19.2% from what the company reported a year ago. Autolus Therapeutics currently has a Zacks Rank of #4 (Sell).
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
